January 2, 2018 / 1:16 PM / a year ago

BRIEF-Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S.

Jan 2 (Reuters) - Sanuwave Health Inc:

* SANUWAVE RECEIVES FDA DE NOVO DECISION TO IMMEDIATELY MARKET THE DERMAPACE SYSTEM FOR THE TREATMENT OF DIABETIC FOOT ULCERS IN THE U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below